Recent 8-K filings for VRTX

• July 6, 2026, 9:55 PM ET M&A materiality 0.90 positive item 1.01item 7.01item 8.01item 9.01

  Vertex to acquire Crinetics Pharmaceuticals for $85.00 per share in cash; expected close Q3 2026

  Vertex to acquire Crinetics for $85.00 per share in cash; expected to close in Q3 2026.

• May 4, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Vertex Q1 revenue $2.99B (+8% YoY); reiterates FY2026 guidance; povetacicept BLA submitted for accelerated approval

  Total revenue $2.99B, up 8% vs Q1 2025; GAAP net income $1.0B, non-GAAP $1.1B.

• February 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Vertex reports FY2025 revenue $12.0B (+9% YoY); guides FY2026 revenue $12.95-13.1B

  FY2025 total revenue $12.0B, up 9% YoY; Q4 revenue $3.19B, up 10% YoY.

• November 3, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Vertex Q3 rev $3.08B (+11% YoY), FY guidance refined; povetacicept IgAN BLA on track

  Q3 total revenue $3.08B (+11% vs Q3 2024); GAAP net income $1.1B, non-GAAP $1.2B.

• August 4, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 5.02item 9.01

  Vertex Q2 revenue $2.96B (+12% YoY); CSO Altshuler to retire Aug 2026; Bunnage to succeed

  Q2 revenue $2.96B (+12% YoY); GAAP net income $1.0B vs loss $3.6B last yr; non-GAAP net income $1.2B vs loss $3.3B

• May 19, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01

  Vertex Pharmaceuticals authorizes $4.0B share repurchase program

  Board authorized new $4.0B stock repurchase program (2025 Repurchase Program) with no expiration date.

• May 5, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Vertex Q1 revenue $2.77B (+3% YoY); GAAP net income falls to $646M on $379M impairment; FY guidance raised

  Revenue $2.77B, +3% YoY; US revenue +9% to $1.66B, ex-US -5% to $1.11B due to Russia IP violation.

• March 28, 2025, 7:59 PM ET other material materiality 0.70 negative item 8.01

  Vertex halts VX-264 type 1 diabetes program; expects ~$400M impairment charge

  Phase 1/2 trial of VX-264 for type 1 diabetes fails; program will not advance further.

• February 10, 2025, 6:59 PM ET earnings materiality 0.85 neutral item 2.02item 5.02item 9.01 ◈ executive_change ×3

  Vertex 2024 product revenue $11.02B (+12% YoY); GAAP loss $536M from IPR&D; FY2025 guidance $11.75-12.0B

  Q4 product revenue $2.91B (+16% YoY); full-year product revenue $11.02B (+12%) driven by TRIKAFTA/KAFTRIO.

• December 20, 2024, 6:59 PM ET regulatory materiality 0.85 positive item 7.01

  Vertex receives FDA approval for new CF drug ALYFTREK; wholesale cost $370K/year

  FDA approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for CF in patients 6+ years with at least one F508del mutation.

• November 4, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Vertex Q3 product revenue $2.77B (+12% YoY); raises FY guidance to $10.8-10.9B

  GAAP net income $1.0B; non-GAAP net income $1.1B; cash & securities $11.2B.

• August 1, 2024, 7:59 PM ET earnings materiality 0.85 neutral item 2.02item 9.01

  Vertex Q2 product revenue $2.65B (+6% YoY); raises FY 2024 guidance to $10.65-10.85B

  GAAP net loss of $3.6B in Q2 due to $4.4B AIPR&D charge from Alpine acquisition.

• June 27, 2024, 7:59 PM ET other material materiality 0.65 neutral item 8.01

  Vertex expects $4.4B AIPR&D charge and $200M compensation expense from Alpine acquisition in Q2 2024

  Vertex records one-time non-deductible AIPR&D expense of approx. $4.4B in Q2 2024 from Alpine asset acquisition accounting.

• May 20, 2024, 7:59 PM ET M&A materiality 0.75 neutral item 8.01item 9.01

  Vertex completes $5.0B acquisition of Alpine Immune Sciences on May 20, 2024

  Acquisition of Alpine for approximately $5.0B in equity value completed.

• May 6, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Vertex Q1 product revenue $2.69B (+13% YoY); reiterates FY guidance; $4.9B Alpine acquisition

  Q1 product revenue $2.69B, up 13% YoY; GAAP net income up 57%; Non-GAAP net income up 56%.

• April 11, 2024, 7:59 PM ET M&A materiality 0.85 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Vertex to acquire Alpine Immune Sciences for $65 per share in all-cash tender offer

  Vertex agrees to buy Alpine Immune Sciences at $65/share via tender offer followed by a merger.

• February 5, 2024, 6:59 PM ET earnings materiality 0.90 positive item 2.02item 9.01 ◈ Earnings Releases

  Vertex Q4/FY23 revenue $2.52B/$9.87B; FY24 guidance $10.55-$10.75B; vanza triple and VX-548 NDAs by mid-2024

  FY23 product revenue $9.87B (+11% YoY); Q4 revenue $2.52B (+9% YoY).

• December 8, 2023, 6:59 PM ET regulatory materiality 0.90 positive item 8.01

  FDA approves Vertex's CASGEVY gene therapy for sickle cell disease at $2.2M list price

  On Dec 8, 2023, FDA approved CASGEVY (exagamglogene autotemcel) for sickle cell disease in patients 12+ with recurrent vaso-occlusive crises.

• November 6, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Vertex Q3 product revenue $2.48B (+6% YoY); raises FY2023 guidance to ~$9.85B

  Product revenue $2.48B (+6% YoY); U.S. $1.55B (+7%), ex-U.S. $929M (+6%).

• August 1, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Vertex Q2 product revenue $2.49B (+14% YoY); raises FY 2023 guidance to $9.7-9.8B

  Q2 product revenue $2.49B, up 14% vs Q2 2022; U.S. revenue $1.51B (+7%), OUS $985M (+26%).

• May 1, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Vertex Q1 product rev $2.37B (+13%); net income down 8% on higher R&D; FY23 guidance unchanged

  Product revenue $2.37B (+13% YoY); U.S. $1.40B (+3%), ex-U.S. $971M (+33%).

• February 7, 2023, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Vertex reports FY22 product revenue $8.93B (+18% YoY); guides FY23 $9.55-$9.7B

  Full year 2022 product revenue $8.93B, up 18% vs 2021; GAAP net income $3.32B, up 42%.

• October 27, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Vertex Q3 product revenue $2.33B (+18% YoY); raises FY22 guidance to $8.8-8.9B

  Product revenue $2.334B, up 18% from Q3 2021; TRIKAFTA/KAFTRIO contributed $2.011B.

• August 4, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Vertex Q2 product revenue $2.20B (+22% YoY); raises FY2022 guidance to $8.6-$8.8B

  Product revenues $2.20B, up 22% YoY; TRIKAFTA/KAFTRIO contributed $1.893B.

• July 11, 2022, 7:59 PM ET M&A materiality 0.70 positive item 8.01item 9.01

  Vertex acquires ViaCyte for $320M cash to accelerate T1D stem cell therapy VX-880

  Vertex to acquire ViaCyte for $320 million in cash; ViaCyte becomes wholly owned subsidiary.

• May 5, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Vertex Q1 product revenue $2.10B (+22% YoY); reiterates FY 2022 guidance $8.4-8.6B

  Product revenues $2.10B (+22% YoY); TRIKAFTA $1.76B (+48% YoY).

• January 26, 2022, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Vertex reports Q4 2021 product revenue $2.07B (+27% YoY); guides 2022 revenue $8.4-$8.6B

  Full-year 2021 product revenue $7.57B (+22% YoY); GAAP diluted EPS $9.01, Non-GAAP $13.02.

• November 2, 2021, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Vertex Q3 revenue $1.98B (+29% YoY); raises FY2021 guidance to $7.4-7.5B

  Product revenues of $1.984B (+29% YoY); GAAP diluted EPS $3.28, Non-GAAP $3.56.

• July 29, 2021, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Vertex Q2 product revenues $1.79B (+18% YoY); raises FY 2021 guidance to $7.2-7.4B

  Product revenues $1.793B, up 18% YoY; TRIKAFTA/KAFTRIO $1.256B led growth.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

21 positive 1 negative 19 neutral

source · VRTX on sec.gov